Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Assembly Biosciences
(NQ:
ASMB
)
15.08
+0.33 (+2.24%)
Streaming Delayed Price
Updated: 12:07 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Assembly Biosciences
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
May 22, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
March 28, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Effective Date of Reverse Stock Split
February 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Provides Anticipated Development Milestones for 2024
January 04, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 04, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 24, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
October 05, 2022
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.